The Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis Patients with Gefapixant, a P2x3 Receptor Antagonist

2019 ◽  
Author(s):  
F.J. Martinez ◽  
A. Afzal ◽  
M.M. Kitt ◽  
A. Ford ◽  
J.J. Li ◽  
...  
Keyword(s):  
Idiopathic Pulmonary Fibrosis ◽  
Pulmonary Fibrosis ◽  
Receptor Antagonist ◽  
Chronic Cough ◽  
P2x3 Receptor

Azithromycin for the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis: A Randomized Controlled Cross-over Trial

2021 ◽  
Author(s):  
Sabina A. Guler ◽  
Christian Clarenbach ◽  
Martin Brutsche ◽  
Katrin Hostettler ◽  
Anne-Kathrin Brill ◽  
...  
Keyword(s):  
Idiopathic Pulmonary Fibrosis ◽  
Pulmonary Fibrosis ◽  
Chronic Cough ◽  
Randomized Controlled

Baseline patient burden in chronic cough from a Phase 2b clinical trial of gefapixant, a P2X3 receptor antagonist

2019 ◽  
Author(s):  
Surinder S. Birring ◽  
Lorcan Mcgarvey ◽  
Jaclyn Smith ◽  
Alyn Morice ◽  
Mandel Sher ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Receptor Antagonist ◽  
Chronic Cough ◽  
P2x3 Receptor ◽  
Patient Burden

scholarly journals Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial

2020 ◽  
Vol 8 (8) ◽  
pp. 775-785 ◽  
Author(s):  
Jaclyn A Smith ◽  
Michael M Kitt ◽  
Alyn H Morice ◽  
Surinder S Birring ◽  
Lorcan P McGarvey ◽  
...  
Keyword(s):  
Receptor Antagonist ◽  
Chronic Cough ◽  
P2x3 Receptor ◽  
Double Blind ◽  
Parallel Group
Sign in / Sign up

Export Citation Format

Share Document